1. Coxibs—Beyond the GI Tract
Anthony N. DeMaria, MD, Matthew R. Weir, MD 
Journal of Pain and Symptom Management 
Volume 25, Issue 2, Pages (February 2003)
DOI: /S (02)

2. Fig. 1 Distribution of COX-1 and COX-2 in the human kidney.
Journal of Pain and Symptom Management  , 41-49DOI: ( /S (02) )

3. Fig. 2 Role of prostaglandins in the kidney.
Journal of Pain and Symptom Management  , 41-49DOI: ( /S (02) )

4. Fig. 3
Vascular events with rofecoxib: meta-analysis of studies of (6 months' duration or more).41 Relative risk (95% CI) of the APTC (Antiplatelet Trialist Collaboration) end point for rofecoxib relative to placebo, non-naproxen NSAIDs, and naproxen in studies ≥6 months in duration. Triangles represent relative risk, and size of triangles represents patient-years of exposure.
Journal of Pain and Symptom Management  , 41-49DOI: ( /S (02) )